<DOC>
	<DOCNO>NCT02286765</DOCNO>
	<brief_summary>Up 20 enrolled subject treat . Subjects receive two Ulthera® treatment axillas provide 30 day apart . Follow-up visit occur 7 , 30 , 90 180 day follow last treatment . Protocol amendment : The study expand enroll additional 20 subject Group A .</brief_summary>
	<brief_title>Ulthera® System Treating Axillary Hyperhidrosis</brief_title>
	<detailed_description>This study prospective , single-center , randomized clinical trial . Up 20 subject naïve Ultherapy treatment hyperhidrosis enrol treat 2.0mm depth two different treatment density ( Group A Group B ) . Group A include 10 treated subject . Subjects receive treatment 3 x 4 grid , 12 treatment square , 60 line treatment per square , one treatment depth ( 2.0mm ) , 0.30 J energy . Group B include 10 treated subject . Subjects receive treatment 3 x 4 grid , 12 treatment square , 40 line treatment per square , one treatment depth ( 2.0mm ) , 0.30 J energy . Gravimetric sweat production measure starch iodine test complete baseline , treatment visit # 2 , follow-up study group . Digital image starch iodine test obtain . Hyperhidrosis Disease Severity Scale ( HDSS ) score obtain baseline , treatment visit , follow-ups study group .</detailed_description>
	<mesh_term>Hyperhidrosis</mesh_term>
	<criteria>Male female , age 1875 year . Subject good health . Diagnosis bilateral axillary hyperhidrosis refractory previous topical therapy . At least 50 mg spontaneous rest axillary sweat production axilla measure gravimetrically room temperature/humidity ( 20 25.6°C/2080 % ) period 5 minute . ( Patients rest least 30 minute physical exercise include walk . ) HDSS score 3 4 . An attempt make approximate equal number score 3 4 . Understands accepts obligation undergo procedure area treat followup period . Willingness ability comply protocol requirement , include return followup visit abstain exclusionary procedure duration study . Subjects childbearing potential must negative urine pregnancy test result must lactate Screening Visit willing able use acceptable method birth control ( e.g . barrier method use spermicidal agent , hormonal method , IUD , surgical sterilization , abstinence ) study . Women consider childbearing potential one follow condition document medical history : 1 . Postmenopausal least 12 month prior study ; 2 . Without uterus and/or ovary ; 3 . Bilateral tubal ligation least six month prior study enrollment . Absence physical psychological condition unacceptable investigator . Willingness refrain use aspirin , Ibuprofen , Naproxen NSAID , Vitamin E 2 week prior study treatment . Willingness ability provide write informed consent HIPAA authorization prior performance studyrelated procedure . Dermal disorder include infection anticipate treatment site either axilla . Previous botulinum toxin treatment axilla past year . Expected use botulinum toxin treatment disease study period . Known allergy starch powder , iodine , lidocaine , epinephrine . Secondary hyperhidrosis , example , hyperhidrosis secondary underlying disease include hyperthyroidism , lymphoma malaria . Previous surgical treatment hyperhidrosis include sympathectomy , surgical debulking sweat gland , subcutaneous tissue curettage ultrasonic surgery . Unwillingness wash deodorant abstain use 72 hour prior treatment assessment . Subjects history bleed disorder Active implant ( e.g. , pacemaker defibrillator ) , metallic implant treatment area . ) Use cholinomimetics , anticholinergic , oral herbal medicine treatment hyperhidrosis . Inability withhold use antiperspirant deodorant , topical treatment hyperhidrosis within 72 hour prior study treatment assessment . Unwillingness complete shave removal underarm hair within 12 hour prior study treatment followup visit . Women pregnant , lactate , possibly pregnant planning pregnancy study period . Inability understand protocol give inform consent . History chronic drug alcohol abuse . History autoimmune disease . Concurrent therapy , investigator 's opinion , would interfere evaluation safety efficacy study device . Subjects anticipate need surgery overnight hospitalization study . Subjects , investigator 's opinion , history poor cooperation , noncompliance medical treatment , unreliability . Concurrent enrollment study involve use investigational device drug . Use antiplatelet agent / Anticoagulants ( Coumadin , Heparin , Plavix ) past 6 week ; Psychiatric drug investigator opinion would impair subject understand protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Ulthera System</keyword>
	<keyword>Ultherapy</keyword>
</DOC>